Cardiol Therapeutics Inc. (CRDL) Revenue History
Annual and quarterly revenue from 2017 to present
CRDL Revenue Over Time (2017–2025)
CRDL Revenue Growth History
0 of 1 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -100.0%
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
CRDL Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 28, 2026, Cardiol Therapeutics Inc. (CRDL) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
CRDL's historical revenue data shows various trends over time. Cardiol Therapeutics Inc.'s highest annual revenue of $62,267 was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including ARWR (+14.1% YoY), TELA (+13.5% YoY), and MDGL (+256.8% YoY). Compare CRDL vs ARWR →
CRDL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CRDLCurrent | $0 | - | - | - | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 TELA | $80M | +13.5% | +34.5% | -42.0% | |
 MDGL | $958M | +256.8% | - | -31.3% |
CRDL Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-34,316,296 | - |
| 2024 | $0 | - | $0 | - | $-40,276,651 | - |
| 2023 | $0 | - | $-187,383 | - | $-22,473,162 | - |
| 2022 | $0 | -100.0% | $-162,226 | - | $-30,493,477 | - |
| 2021 | $62K | - | $-111,997 | -179.9% | $-30,568,391 | -49092.4% |
| 2020 | $0 | - | $-180,171 | - | $-16,240,550 | - |
| 2019 | $0 | - | $-116,114 | - | $-10,894,751 | - |
| 2018 | $0 | - | $-91,492 | - | $-7,390,433 | - |
| 2017 | $0 | - | $-53,341 | - | $-1,589,312 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRDL — Frequently Asked Questions
Quick answers to the most common questions about buying CRDL stock.
Is CRDL's revenue growth accelerating or slowing?
CRDL TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CRDL's revenue history from 2017 to 2026?
Cardiol Therapeutics Inc. (CRDL) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CRDL's long-term revenue growth rate (CAGR)?
Cardiol Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CRDL.
Why does CRDL's quarterly revenue fluctuate?
CRDL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Cardiol Therapeutics Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is CRDL's revenue distributed by segment?
CRDL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CRDL's revenue compare to industry peers?
Cardiol Therapeutics Inc. (CRDL) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.